Since PD-L1 expressed on tumor cells and macrophages is a negative regulator of T cell responses, blocking the PD-1/PD-L1 axis can improve immune responses against tumors (24); furthermore, it makes sense that in a 62-person cohort of NSCLC patients treated with ICIs, high levels of CD68+PD-L1+ immune cells were associated with prolonged OS (25). This evidence concerns the gene CD274 and neoplasm.